Exemption to SII pneumococcal vaccine from price control for 5 years: NPPA
|
Overview
In a major relief to Serum Institute of India, the drug price regulator, the National Pharmaceutical Pricing Authority (NPPA), has decided to grant exemption to Serum Institute of India's (SII) indigenously developed pneumococcal polysaccharide conjugate vaccine against pneumonia from price fixation for a period of five years from the date of commencement of its commercial production in the country, subject to it being co-terminus with the duration of the Indian Patent.
For more information, check out the full story on the link below:
Exemption To SII Pneumococcal Vaccine From Price Control For 5 Years: NPPA
Speakers
Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
